Clinical trials: Colon Neoplasm
Colorectal Cancer, Pancreatic Cancer
BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
This study is an exploratory research on single arm, open, and improved "3+3" dose escalation. BGT007 will explore two dose groups, namely (Group A: 3.0X10 ^ 8 3 cases, Group B: 6.0X10 ^ 8 3 cases), and receive the same dose…
- Trial name
- NCT06645301
- Testing
- Group A, Group B
- Volunteers
- 15 people
- Sponsor
- BioSyngen Pte Ltd
Complete Obstruction
Primary Anastomosis After Left Colectomy in Emergency Cases
The aim of this study is to know the outcome of primary anastomosis after left colectomy in emergency cases regarding early post operative complication like surgical site infection , ileus, incidence of leakage, restoration of…
- Trial name
- NCT07026201
- Testing
- colectomy with primary anastomosis
- Where
- Egypt
- Volunteers
- 37 people
- Sponsor
- Ain Shams University
Metastatic Colorectal Cancer
Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab
-1498C/T VEGF polymorphism, as suggested by a recent retrospective analysis, seems to have a role in predicting the efficacy of Bevacizumab plus FOLFIRI in first-line treatment of metastatic colorectal cancer patients.
- Trial name
- PROVETTA (NCT01363739)
- Where
- Italy
- Volunteers
- 265 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Colorectal Cancer (CRC), Early Onset Colorectal Cancer
Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022
The incidence of early-onset colorectal cancer (EOCRC; patients younger than 50 years) has increased worldwide over recent decades. This study aimed to provide nationwide evidence on surgically treated EOCRC in Switzerland.
- Trial name
- NCT07763314
- Testing
- Early-onset colorectal cancer resection, Late-onset colorectal cancer resection
- Where
- Switzerland
- Volunteers
- 73,771 people
- Sponsor
- Cantonal Hospital of St. Gallen
Colon Rectal Cancer Duke Stage Stageval
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer
- Trial name
- NCT01310985
- Testing
- Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Colo-rectal Cancer, Colon Cancer
Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)
To understand and analyse the global impact of COVID-19 on outpatient services, inpatient care, elective surgery, and perioperative colorectal cancer care, a DElayed COloRectal cancer surgery (DECOR-19) survey was conducted in…
- Conditions
- Colo-rectal Cancer, Colon Cancer, Rectal Cancer, Oncology
- Trial name
- DECOR-19 (NCT04488549)
- Testing
- Survey
- Where
- Italy
- Volunteers
- 1,051 people
- Sponsor
- Treviso Regional Hospital
Metastatic Colorectal Cancer
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to…
- Trial name
- NCT01533740
- Testing
- fluorouracil/irinotecan/levo-folinic acid/bevacizumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Rome Tor Vergata
Colorectal Neoplasms
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
- Trial name
- CRLM (NCT07564908)
- Testing
- Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Meng Qiu
Colon Cancer Stage III
Lymph Node Ratio and Kras Mutation in R Colon Cancer
clinical impact of LN ratio with Kras expression in colon cancer
- Trial name
- NCT04342676
- Testing
- k ras, Panitumumab
- Where
- Egypt
- Volunteers
- 433 people
- Sponsor
- Mansoura University
Metastatic Colorectal Cancer
Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan
Primary Endpoint : To evaluate the Disease control rate (DCR) Secondary Endpoints: To evaluate the Progression-free survival (PFS), Overall survival(OS) and Safety profile
- Trial name
- NCT06495463
- Testing
- Trifluridine/tipiracil
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Chang Gung Memorial Hospital
Colostomy, Colorectal Neoplasm
A Randomized Trial on the Technical Aspects of Stoma Construction.
An investigation on the difference in stoma hernia frequency related to surgical technique when incising the fascia. All patients planned for elective colostomy formation are to be included.
- Conditions
- Colostomy, Colorectal Neoplasm, Diverticulitis
- Trial name
- NCT01694238
- Testing
- Cruciate incision, Circular incision, Mesh enforced cruciate incision
- Where
- Sweden
- Volunteers
- 209 people
- Sponsor
- Sahlgrenska University Hospital
Colorectal Cancer
Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer
Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total
- Trial name
- NCT03566355
- Testing
- curative proton therapy
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- National Cancer Center, Korea
Colo-rectal Cancer
Clinical Study on the Expression of PHGDH and Its Prognostic Value in Colorectal Cancer Patients Receiving Immunotherapy
This study aims to evaluate the expression characteristics of PHGDH in tumor tissues based on the clinical data and pathological tissue samples of colorectal cancer patients who have previously received immunotherapy, and to…
- Trial name
- NCT07508046
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- West China Hospital
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer, Refractory Colorectal Cancer
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT06202417
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Fudan University
Familial Adenomatous Polyposis, Colorectal Cancer
Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)
The goal of this research study is to test the first version of a website that will offer information and support for adolescents and young adults with FAP.
- Trial name
- NCT00525655
- Testing
- Web-Based Multimedia Intervention, Questionnaire
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer (CRC), Surgery, Colorectal
Study of Colorectal Anastomosis Failures With First Sigmoid or Left Colonic Artery Preservation With D3 Lymphadenectomy
This study is a randomized, controlled trial comparing the short- and long-term outcomes of left colonic artery or first sigmoid artery preservation for rectal surgery.
- Conditions
- Colorectal Cancer (CRC), Surgery, Colorectal, Oncology
- Trial name
- COLAP-D3 (NCT06938490)
- Testing
- Anterior rectal resection with D3-lymphatic dissection
- Where
- Russia
- Volunteers
- 778 people
- Sponsor
- the BELOOSTROV Clinic of High Technologies
Colon Rectal Cancer, Surgical Site Infection
Surveillance and Implementation of a Bundle of Care to Reduce Surgical Site Infection in Colorectal Surgery (CCR-VINCat)
The Nosocomial Infection Surveillance Program in Catalonia (VINCat) monitors surgical site infection (SSI) in elective colorectal surgery since 2007 in 55 public and private acute care hospitals.
- Trial name
- CCR-VINCat (NCT04496635)
- Testing
- Implementation of a bundle of care
- Where
- Spain
- Volunteers
- 60,000 people
- Sponsor
- Hospital de Granollers
Breast Cancer, Colo-rectal Cancer
Cancer Mortality Affected by the Choice of Anesthetic Drugs?
Knowledge gap: Does the choice of anaesthetic affect outcome for cancer surgery? Aim: To retrospectively examine possible associations (Cox Multiple Regression) between survival from breast-, colorectal-, or skin cancer and the…
- Conditions
- Breast Cancer, Colo-rectal Cancer, Skin Cancer
- Trial name
- NCT01418326
- Where
- Sweden
- Volunteers
- 3,284 people
- Sponsor
- Enlund
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma
- Trial name
- NCT04500548
- Testing
- Biospecimen Collection, Ipilimumab, Nivolumab
- Where
- 9 sites in United States, Canada
- Sponsor
- National Cancer Institute (NCI)